Vaxcyte Inc
PCVX56.150USD
+2.240+4.16%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
7.30BValor de mercado
PerdaP/L TTM
Mais detalhes de Vaxcyte Inc Empresa
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Informações de Vaxcyte Inc
Código da empresaPCVX
Nome da EmpresaVaxcyte Inc
Data de listagemJun 12, 2020
CEOPickering (Grant E)
Número de funcionários414
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 12
Endereço825 Industrial Road, Ste. 300
CidadeSAN CARLOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94070
Telefone16508370111
Sitehttps://vaxcyte.com/
Código da empresaPCVX
Data de listagemJun 12, 2020
CEOPickering (Grant E)
Executivos da empresa Vaxcyte Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
558.46K
-100000.00%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-7045.00%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
13.74K
-61850.00%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-5102.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+3041.00%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+3041.00%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
+3041.00%
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
+3041.00%
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
2.50K
+1357.00%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
558.46K
-100000.00%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-7045.00%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
13.74K
-61850.00%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-5102.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+3041.00%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+3041.00%
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 15 de nov
Atualizado em: sáb, 15 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
9.29%
The Vanguard Group, Inc.
8.63%
RA Capital Management, LP
8.48%
Fidelity Management & Research Company LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.95%
Outro
60.32%
Investidores
Investidores
Proporção
Janus Henderson Investors
9.29%
The Vanguard Group, Inc.
8.63%
RA Capital Management, LP
8.48%
Fidelity Management & Research Company LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.95%
Outro
60.32%
Tipos de investidores
Investidores
Proporção
Investment Advisor
40.76%
Investment Advisor/Hedge Fund
28.90%
Hedge Fund
17.96%
Venture Capital
10.55%
Research Firm
2.07%
Sovereign Wealth Fund
0.70%
Pension Fund
0.54%
Individual Investor
0.50%
Bank and Trust
0.43%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
698
144.29M
102.33%
-18.18M
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
13.10M
10.01%
-1.59M
-10.80%
Sep 30, 2025
The Vanguard Group, Inc.
12.29M
9.39%
+323.37K
+2.70%
Sep 30, 2025
RA Capital Management, LP
11.97M
9.14%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
10.34M
7.9%
+289.69K
+2.88%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
6.41%
-654.49K
-7.24%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
8.32M
6.35%
+2.31M
+38.56%
Sep 30, 2025
Wellington Management Company, LLP
5.03M
3.84%
+77.97K
+1.57%
Sep 30, 2025
State Street Investment Management (US)
4.79M
3.66%
-156.35K
-3.16%
Sep 30, 2025
D. E. Shaw & Co., L.P.
4.29M
3.28%
+1.20M
+38.93%
Sep 30, 2025
Paradigm BioCapital Advisors LP
3.78M
2.89%
+411.92K
+12.21%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.39%
State Street SPDR S&P Biotech ETF
1.65%
Direxion Daily S&P Biotech Bull 3X Shares
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ProShares Ultra Nasdaq Biotechnology
0.58%
Invesco Nasdaq Biotechnology ETF
0.57%
iShares Biotechnology ETF
0.5%
JPMorgan Fundamental Data Science Small Core ETF
0.44%
iShares Russell 2000 Value ETF
0.34%
Ver Mais
Harbor Health Care ETF
Proporção4.32%
ALPS Medical Breakthroughs ETF
Proporção2.39%
State Street SPDR S&P Biotech ETF
Proporção1.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.89%
ProShares Ultra Nasdaq Biotechnology
Proporção0.58%
Invesco Nasdaq Biotechnology ETF
Proporção0.57%
iShares Biotechnology ETF
Proporção0.5%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.44%
iShares Russell 2000 Value ETF
Proporção0.34%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
